Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Keeps Halo Pharma to drive independent growth
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
